Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Concurrent use of trastuzumab and chemotherapy significantly reduces recurrence
June 9th, 2005
A study led by a Mayo Clinic researcher in Jacksonville, Florida, and conducted by the North Central Cancer Treatment Group (NCCTG) has provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and the monoclonal antibody trastuzumab (Herceptin). According to Mayo Clinic medical oncologist and NCCTG study chair Edith Perez, MD, these results could change the standard of care for thousands of women with breast cancer. "Women with HER-2 positive breast cancer had a high risk of the cancer returning and of dying from breast cancer. This intervention - chemotherapy plus trastuzumab - essentially...
Source: Women's Health Weekly (2005-06-09)
|
